• No results found

May antihistone antibodies replace antinuclear antibodies (ANA) as a predictor of uveitis in Juvenile idiopathic arthritis?

N/A
N/A
Protected

Academic year: 2022

Share "May antihistone antibodies replace antinuclear antibodies (ANA) as a predictor of uveitis in Juvenile idiopathic arthritis?"

Copied!
1
0
0

Laster.... (Se fulltekst nå)

Fulltekst

(1)

BioMed Central

Page 1 of 1

(page number not for citation purposes)

Pediatric Rheumatology

Open Access

Poster presentation

May antihistone antibodies replace antinuclear antibodies (ANA) as a predictor of uveitis in Juvenile idiopathic arthritis?

EB Nordal*

1

, NT Songstad

2

, B Straume

3

, L Berntson

4

and M Rygg

5

Address: 1Department of Pediatrics, University Hospital of North Norway and Institute of Community Medicine, University of Tromsø, Tromsø, Norway, 2Department of Pediatrics, University Hospital of North Norway, Tromsø, Norway, 3Institute of Community Medicine, University of Tromsø, Tromsø, Norway, 4Department of Women's and Children's Health, Uppsala University Children's Hospital, Uppsala, Sweden and

5Department of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology and Department of Pediatrics, St. Olavs Hospital, Trondheim, Norway

* Corresponding author

Background

Antihistone antibodies (AHA) are an ANA subtype reported to be associated with uveitis in Juvenile idio- pathic arthritis (JIA). Enzyme-linked immunoassays (E- ANA) are increasingly used as a more standardized alter- native to the immunofluorescense method on Hep-2 cells (IF-ANA). E-ANA, however, show no association with uveitis and should not be used in the diagnostic work-up of JIA.

Materials and methods

Sera of 100 children with JIA and 60 healthy children were analyzed for antihistone IgM/IgG (Pharmacia ELIA kit), for E-ANA and IF-ANA. Patients were recruited prospec- tively and followed at regular intervals from onset of dis- ease in 1997–2004.

Results

Of the 100 children with JIA, 16 developed asymptomatic chronic uveitis; mean observation time was seven years.

Antihistone IgM/IgG > 30 U/ml were found in six of the 100 children with JIA, four of whom developed uveitis, and in one of the controls. However, exploring lower cut- off levels of AHA, we found uveitis in 13 of 44 patients with AHA > 8 U/ml. Analyses of predictors for uveitis show that young age at onset of arthritis, AHA > 8 U/ml and IF-ANA titer > 1/320 carry significantly increased risk of developing uveitis. No significant increased risk is

found for the oligoarthritis subtype, female gender, posi- tive E-ANA and IF-ANA titer > 1/80.

Conclusion

Antihistone IgM/IgG are significantly associated with uveitis in JIA children. AHA at a low cut-off level, show comparable test performance as IF-ANA, in predicting uveitis. As E-ANA replaces IF-ANA in many laboratories, further studies are needed to confirm the value of the AHA in risk stratification for uveitis screening.

from 15th Paediatric Rheumatology European Society (PreS) Congress London, UK. 14–17 September 2008

Published: 15 September 2008

Pediatric Rheumatology 2008, 6(Suppl 1):P4 doi:10.1186/1546-0096-6-S1-P4

<supplement> <title> <p>15<sup>th </sup>Paediatric Rheumatology European Society (PreS) Congress</p> </title> <editor>Wietse Kuis, Patricia Woo, Angelo Ravelli, Hermann Girschick, Michaël Hofer, Johannes Roth, Rotraud K Saurenmann, Alberto Martini, Pavla Dolezova, Janjaap van der Net, Pierre Quartier, Lucy Wedderburn and Jan Scott</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/PDF/1546-0096-6-S1-full.pdf">here</a>.</note> </supplement>

This abstract is available from: http://www.ped-rheum.com/content/6/S1/P4

© 2008 Nordal et al; licensee BioMed Central Ltd.

Referanser

RELATERTE DOKUMENTER

ping, Sweden, h Tromsø Endocrine Research Group, Institute of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway, i Division of Internal Medicine,

a Department of Infectious Diseases, Medical clinic, University Hospital of North Norway, Tromso, Norway; b Department of Community Medicine, University of Tromsø – The

1 Norwegian Polar Institute, Fram Centre, NO-9296 Tromsø, Norway, 2 Department of Biological Sciences, University of Bergen, NO-5020 Bergen, Norway, 3 Norwegian Institute for

1 Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway, 2 Department of Medical Biology, The Arctic University of Norway, Tromsø,

b Department of Pharmaceutics and Biopharmaceutics, University of Tromsø, 9037 Tromsø, Norway, c Research Center Borstel, Leibniz Center for Medicine and Biosciences, D-23845

a Department of Chemistry, University of Tromsø, 9037 Tromsø, Norway, b Department of Pharmaceutics and Biopharmaceutics, University of Tromsø, 9037 Tromsø, Norway, and c Institute

a Department of Chemistry, University of Tromsø, 9037 Tromsø, Norway, b Department of Pharmaceutics and Biopharmaceutics, University of Tromsø, 9037 Tromsø, Norway, and c Institute

Documentation and Evaluation, Northern Norway Regional Health Authority trust, Tromsø, Norway; e Department of Cardiology, University Hospital of North Norway, Tromsø, Norway;